IBA divests PharmaLogic PET Services

Radiopharmaceutical provider Ion Beam Applications (IBA) has sold the assets of its PharmaLogic PET Services of Montreal subsidiary to a private equity firm.

Approximately 85% of the price has been paid for the PharmaLogic assets at closing, and the rest will be paid after a two-year period, IBA said. Payments will then be distributed as dividends to PharmaLogic's shareholders, including IBA.

IBA expects a net total cash inflow from this sale of approximately 7.7 million euros ($10.4 million U.S.).

Olivier Legrain, CEO of IBA, said the sale follows the company's strategy to divest noncore assets to focus IBA on proton therapy and associated technologies.

Latest in Clinical News
Page 1 of 1291
Next Page